Volume 5, Number 1
Monday, January 10, 2005



In this issue: (click heading to view article)
Studying Tear Flow Dynamics in the Nasolacrimal Ducts Using Dynamic Magnetic Resonance Imaging
Inflammatory Cytokines Induce Apoptosis of Corneal Endothelium Through Nitric Oxide
Pre-op Conjunctival Bacterial Flora in Patients Undergoing Glaucoma vs. Cataract Surgery
Briefly











Studying Tear Flow Dynamics in the Nasolacrimal Ducts Using Dynamic Magnetic Resonance Imaging

A prevailing theory of tear drainage suggests that the lacrimal sac fills when the eyelids are closed and empties into the nasolacrimal duct when the eyelids are open. This is aided by the contraction of the orbicularis muscle during each blink. The Eye Institute at the National University Hospital in Singapore undertook a study to ascertain the possibility of seeing the dynamic movement of tears in the nasolacrimal system during blinks, using magnetic resonance dacryocystography (MR-DCG).

Researchers initially localized the lacrimal sac with a three-plane gradient echo sequence using a 1.5-T MRI platform. They then carried out fast, dynamic MR-DCG after instilling topically balanced salt solution (BSS) in five subjects and 0.5% gadolinium in seven subjects. The volunteers were asked to close and open their eyes during the fast imaging. The images were digitized to enable investigators to see the actual movement of fluid in the system.

The tear movement was clearly seen as a bolus in the volunteers where BSS was used. The fluid passed into the nasolacrimal duct after several blinks when patent; the sac was never seen to empty completely. Though researchers saw differential filling between the upper and lower part of the sac, they had difficulty seeing the actual fluid movement in the volunteers when topical gadolinium was used. Their findings support the notion of fluid travel in the form of a bolus through the sac. Once a threshold volume is reached in the lower end of the sac, the fluid is seen to pass through the nasolacrimal duct. This happens after several blinks.

SOURCE: Amrith S, Goh PS, Wang SC. Tear flow dynamics in the human nasolacrimal ducts-a pilot study using dynamic magnetic resonance imaging. Graefes Arch Clin Exp Ophthalmol 2004 Dec 17 [Epub ahead of print].
Table of Contents











Inflammatory Cytokines Induce Apoptosis of Corneal Endothelium Through Nitric Oxide

Proinflammatory cytokines are integral components of the allogeneic response to a corneal transplant and contribute to the pathogenesis of graft failure that results from irreversible damage to donor corneal endothelium. As yet, the mechanism and effectors of tissue damage during graft rejection remain unidentified. London’s Imperial College recently investigated the synergistic apoptotic effect of sustained proinflammatory cytokine insult in excised cornea and in transformed and primary corneal endothelial cells.

Investigators assessed apoptosis using tissue- and flow cytometry–based terminal deoxynucleotidyl transferase nick end labeling (TUNEL). They studied downstream signaling events of cytokine stimulation and subsequent activation status of endothelium by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot analysis. Cellular production of nitric oxide was examined by the Griess reaction.

Prolonged exposure (48 hours) of corneal endothelium to IL-1, IFNgamma, and TNF (100 ng/mL each) resulted in induction of apoptosis. Investigators found synergy in induction of apoptosis after exposure to cytokine combinations. Cytokine-mediated cytotoxicity was correlated with high and sustained (up to 36 hours) endothelial activation, upregulation of inducible nitric oxide synthase (iNOS) and elevated de novo production of nitric oxide. Pharmacologic inhibition of iNOS elicited complete cytoprotection from inflammatory cytokine insult. The results suggest that inflammatory cytokine-induced apoptosis presents a new target for the development of interventions to prevent or attenuate endothelial injury in graft rejection.

SOURCE: Sagoo P, Chan G, Larkin DF, George AJ. Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Invest Ophthalmol Vis Sci 2004;45(11):3964-73.
Table of Contents











Pre-op Conjunctival Bacterial Flora in Patients Undergoing Glaucoma vs. Cataract Surgery

Investigators at Stanford University’s School of Medicine recently conducted a prospective study comparing conjunctival bacterial cultures from patients undergoing either cataract or glaucoma surgery to determine whether differences were evident between the two groups of patients.

Cultures were obtained from 339 patients undergoing either cataract surgery (258 patients) or glaucoma surgery (81 patients). All cultures were acquired during the pre-operative visit approximately three to seven days before surgery. Researchers inoculated the culture samples onto blood and chocolate agar, as well as blood culture broth media. They identified all bacterial isolates and performed statistical analyses to determine whether any differences in flora existed between the two types of patients.

Of those undergoing cataract surgery, 215 (83 percent) had positive bacterial growth, compared with 62 of 81 eyes (77 percent) of those undergoing glaucoma surgery. Coagulase-negative Staphylococci, the most common bacterial isolate, was cultured from 167 eyes (65 percent) in the cataract group and 42 (52 percent) in the glaucoma group. Among all bacterial isolates, only Corynebacterium species was found to be statistically different between the two patient groups, with 92 (36 percent) and 11 (14 percent) eyes testing positive in the cataract and glaucoma groups, respectively.

The authors concluded that no statistically significant difference exists in the proportion of conjunctival culture samples testing positive for bacterial growth in eyes undergoing glaucoma surgery compared with those undergoing cataract surgery. Glaucoma medications or their preservatives do not appear to significantly alter conjunctival flora. Techniques used for endophthalmitis prophylaxis before cataract surgery are likely appropriate for glaucoma surgery as well.

SOURCE: de Kaspar HM, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma 2004;13(6):507-9.
Table of Contents





BRIEFLY
  • COOPER COMPANIES COMPLETES MERGER WITH OCULAR SCIENCES. The Cooper Companies, Inc., recently announced that its merger with Ocular Sciences, Inc., has been completed. At closing, Cooper paid approximately $600 million in cash and issued approximately 10.7 million shares of its common stock to Ocular Sciences stockholders and option holders. The Cooper Companies" CooperVision unit, the world"s fourth-largest contact lens manufacturer, is a leading global supplier of specialty contact lenses. Ocular Sciences, the world"s fifth-largest contact lens manufacturer, supplies primarily spherical and daily disposable contact lenses. With the completion of the merger, CooperVision becomes the world"s third-largest contact lens company.
  • GENAERA’S SQUALAMINE CHOSEN FOR FDA CMA PILOT 2 PROGRAM. The FDA has selected squalamine, Genaera Corporation’s systemically administered anti-angiogenic small molecule, for participation in its Continuous Marketing Application (CMA) Pilot 2 program. Genaera is developing squalamine for the treatment of wet age-related macular degeneration (AMD); it is currently undergoing three Phase II trials for treatment of AMD at multiple sites throughout the United States. Participation in the Pilot 2 program is limited to only one Fast Track product for each review division within the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). Squalamine was selected by CDER"s Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products. In October 2004, the FDA granted it Fast Track status. The CMA Pilot 2 program provides for frequent scientific feedback and interactions during the Investigational New Drug phase of development, based on a defined agreement between the FDA and the applicant. The FDA initiated the CMA Pilot 2 program to evaluate the costs and benefits of increased sponsor access to guidance and feedback from the FDA for Fast Track products. For information about participation in squalamine clinical trials, call Genaera"s Clinical Trial Hotline at 800-299-9156.
  • ALLABOUTVISION.COM TRAFFIC UP 50 PERCENT IN 2004. Growing consumer demand for online eye health and vision correction information boosted visitor traffic on AllAboutVision.com by 50 percent in 2004, according to the company’s publisher, Tom Meinert. LASIK and eye conditions including glaucoma, macular degeneration, astigmatism and cataracts were among the most popular topics for the more than 4.8 million unique visitors to the site. Citings in the Wall Street Journal and Newsweek also contributed to traffic growth. Online since January 2000, AllAboutVision.com provides consumers with more than 450 pages of up-to-date doctor-reviewed content. The site is published by Access Media Group, LLC, a print and electronic communications company specializing in vision care. For more information, contact Ron Walker at 610-492-1033 or go to www.AllAboutVision.com/prof/.
  • COLLAGEN MATRIX DEVELOPED TO PREVENT SCAR FORMATION IN GLAUCOMA FILTRATION MICROSURGERY. The Pro Top and Mediking Companies of Taiwan recently announced that they have successfully developed a scarring inhibitor for glaucoma filtration microsurgery and other ophthalmic surgical procedures. The inhibitor, called OculusGen, is a biodegradable, three-dimensional, porous collagen-glycosaminoglican scaffold that helps prevent scar formation and creates a physiological aqua buffer environment for modulating the trabeculectomy and other ophthalmic surgeries, including pterygium, ocular plastic, strabismus correction, conjunctiva scar removal, orbital and nasolacrimal duct surgery. OculusGen was developed and patented by Life Spring Biotechnology Company Limited. Pro Top and Mediking are processing an application for the CE Mark for OculusGen, and they expect to attain the mark before summer 2005. For more information, go to www.OculusGen.com.

Table of Contents



 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It"s only been up and running a few short weeks. Yet, it"s already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers" eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.